SecurityCIDM / Cinedigm Corp. (172406100)
IndustryVideo Tape Rental
Institutional Owners23
Institutional Shares2,701,961 - 7.70%
Common Shares Outstanding35,068,853 shares (as of 2018-06-30)
Institutional Value$ 4,055,000 USD

Institutional Stock Ownership and Shareholders()

CIDM / Cinedigm Corp. Institutional Ownership

Cinedigm Corp. (NASDAQ:CIDM) has 23 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,701,961 shares. Largest shareholders include Zazove Associates Llc, Renaissance Technologies LLC, Thrivent Financial For Lutherans, Vanguard Group Inc, Angelo Gordon & Co., L.p., BlackRock Inc., Fifth Third Bancorp, Acadian Asset Management Llc, Clear Harbor Asset Management, LLC, and Cannell Peter B & Co Inc.
Cinedigm Corp. (NASDAQ:CIDM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-14 13F-HR BARCLAYS PLC 5,625 14,695 161.24 8 23 187.50
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 1,079 1,061 -1.67 1 2 100.00
2018-08-13 13F-HR MATRIX ASSET ADVISORS INC/NY 12,365 12,365 0.00 17 19 11.76
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 1 1 0.00 0 0
2018-08-03 13F-HR Clear Harbor Asset Management, LLC 39,350 61
2018-08-13 13F-HR Renaissance Technologies LLC 734,140 1,006
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 19,513 45,447 132.91 27 71 162.96
2018-08-06 13F-HR Cannell Peter B & Co Inc 33,284 52
2018-08-14 13F-HR VANGUARD GROUP INC 253,394 253,394 0.00 347 393 13.26
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 12,105 0 -100.00 17 0 -100.00
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 11,696 0 -100.00 16 0 -100.00
2018-07-30 13F-HR/A Virtu Financial LLC 0 11,459 0 18
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 29,345 29,345 0.00 40 45 12.50
2017-02-10 13F-HR BlackRock Fund Advisors 2,015 2,555 26.80 4 4 0.00
2018-08-14 13F-HR DEUTSCHE BANK AG\ 0 24,483 0 37
2018-08-14 13F-HR UBS Group AG 9,464 2,046 -78.38 13 3 -76.92
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 17,075 0 -100.00 23 0 -100.00
2018-08-09 13F-HR BlackRock Inc. 19,583 60,581 209.36 27 95 251.85
2018-08-14 13F-HR PEAK6 Investments, L.P. 669,375 0 -100.00 917 0 -100.00
2018-08-09 13F-HR ZAZOVE ASSOCIATES LLC 1,019,182 851,248 -16.48 1,396 1,319 -5.52
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 10,970 10,970 0.00 15 17 13.33
2018-08-14 13F-HR FIFTH THIRD BANCORP 53,500 53,500 0.00 73 83 13.70
2018-08-14 13F-HR NORTHERN TRUST CORP 14,212 19,012 33.77 19 29 52.63
2018-08-14 13F-HR ROYAL BANK OF CANADA 7 0 -100.00 0 0
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 10,671 10,671 0.00 22 15 -31.82
2018-08-14 13F-HR MORGAN STANLEY 17 3,510 20,547.06 0 5
2018-08-13 13F-HR ANGELO GORDON & CO., L.P. 137,757 137,757 0.00 189 214 13.23

Related Articles

REPH: Recro Pharma Analysis and Research Report

10h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

11h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

11h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

Cinedigm's (CIDM) CEO Chris McGurk on Q1 2019 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Good day, ladies and gentlemen, and thank you for your patience. You joined the Cinedigm Corp. Fiscal 2019 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference may be recorded. (3-0)

Cinedigm Corp.'s (CIDM) CEO Chris McGurk on Q4 2018 Results - Earnings Call Transcript

2018-06-26 seekingalpha
Good day, ladies and gentlemen, and welcome to the Cinedigm Corporation fiscal 2018 fourth-quarter and full-year earnings call. (1-0)

Cinedigm Corp.'s (CIDM) CEO Chris McGurk on Fiscal Q4 2018 Results - Earnings Call Transcript

2018-06-26 seekingalpha
Good day, ladies and gentlemen, and welcome to the Cinedigm Corporation fiscal 2018 fourth-quarter and full-year earnings call. (1-0)

Silicon Investor Message Boards

This table lists all message boards related to CIDM / Cinedigm Corp. on message board site Silicon Investor.

CIDM - Cinedigm Digital Cinema Corp. CIDM - Cinedigm Digital Cinema Corp. CIDM - Cinedigm Digital Cinema Corp.
CUSIP: 172406100